Table 2 Placebo-subtracted changes from baseline at 6 months.

Placebo-subtracted changes from baseline at 6 months.. Data are presented as LSM (least squares mean) changes (95% CI).

TTP399 (400 mg)
(n = 50)
TTP399 (800 mg)
(n = 42)
Sitagliptin
(n = 49)
HbA1c, %−0.2 (−0.8 to 0.5)−0.9 (−1.5 to −0.3)**−1.0 (−1.5 to −0.5)
FPG, mg/dl5.5 (−19.6 to 30.5)−4.8 (−31.0 to 21.5)−16.6 (−41.8 to 8.6)
Weight, kg−0.11 (−1.6 to 1.4)−1.2 (−2.7 to 0.3)0.5 (−1.0 to 1.9)
  Weight in patients ≥100 kg−0.2 (−2.7 to 2.4)−3.4 (−6.2 to −0.6)*−0.6 (−3.1 to 2.0)
Insulin, μIU/ml0.67 (−4.3 to 5.6)1.22 (−4.4 to 6.9)−1.3 (−7.3 to 4.7)
Glucagon, ng/liter−8.1 (−24.2 to 8.0)−19.6 (−34.8 to −4.4)*−2.0 (−17.0 to 13.0)
GLP-1, ng/liter10.6 (−12.7 to 33.8)0.4 (−15.1 to 15.9)18.2 (3.3 to 33.0)
C-peptide, μg/liter0.05 (−0.60 to 0.70)−0.19 (−0.82 to 0.44)0.23 (−0.38 to 0.85)
Lipids
  HDL-C, mg/dl−0.4 (−3.4 to 2.6)3.2 (0.2 to 6.1)*0.9 (−1.9 to 3.7)
  Non–HDL-C, mg/dl7.9 (−8.2 to 23.9)2.9 (−13.1 to 18.8)−2.0 (−17.0 to 13.0)
  TG, mg/dl1.5 (−50.0 to 53.1)−13.3 (−59.6 to 33.0)−27.4 (−73.5 to 18.7)
  Total cholesterol, mg/dl5.5 (−11.4 to 22.4)6.9 (−9.8 to 23.6)−2.4 (−17.9 to 13.1)
Lactate, mg/dl0.71 (−2.5 to 3.9)0.93 (−2.3 to 4.1)0.68 (−2.4 to 3.8)

*P < 0.05.

**P < 0.01.